Nombre del producto:4-(2-(4-Bromophenoxy)ethyl)morpholine

IUPAC Name:4-[2-(4-bromophenoxy)ethyl]morpholine

CAS:836-59-9
Fórmula molecular:C12H16BrNO2
Pureza:95%
Número de catálogo:CM279800
Peso molecular:286.17

Unidad de embalaje Stock disponible Precio($) Cantidad
CM279800-5g in stock ȦǕȦ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :836-59-9
Fórmula molecular:C12H16BrNO2
Punto de fusión:-
Código de sonrisas:BrC1=CC=C(OCCN2CCOCC2)C=C1
Densidad:
Número de catálogo:CM279800
Peso molecular:286.17
Punto de ebullición:
Nº Mdl:MFCD01308572
Almacenamiento:

Category Infos

Morpholines
Morpholine contains secondary amine groups and has all the typical reactive characteristics of secondary amine groups. It can react with inorganic acids to form salts, and react with organic acids to form salts or amides, which can be subjected to alkylation reaction, and can also be reacted with ethylene oxide, ketone or Willgerodt reaction. Morpholine is a six-membered ring containing oxygen and nitrogen, and its alkalinity is much lower than that of its parent piperidine. The marketed morpholine drugs are mainly distributed in the fields of tumors, cardiovascular and cerebrovascular diseases, respiratory system diseases, digestive system diseases, infectious diseases and mental disorders.
morpholine price
if you are interested in morpholine price, please feel free to contact us. More information of our products will be forwarded to you upon receipt of your specific inquiry.

Column Infos

Tirbanibulin
Actinic keratosis (AK) is a chronic disease resulting from deleterious effects of long-term, cumulative, epidermal exposure to ultraviolet (UV) light. 
Tirbanibulin is a synthetic, first-in-class, potent anti-proliferative agent that has shown antiproliferative and antitumoral effects in vitro and in vivo by inducing cell cycle arrest and ultimately apoptotic cell death. These effects have been attributed to the ability of tirbanibulin to reversibly bind to the colchicine-binding site on b-tubulin and inhibit tubulin microfilament polymerization.
The U.S. actinic keratosis treatment market size was valued at USD 2.94 billion in 2023 and is projected to reach USD 3.96 billion by 2033, growing at a CAGR of 3.04% from 2024 to 2033.

Related Products